BioCardia, Inc. Files 8-K Report
Ticker: BCDA · Form: 8-K · Filed: Feb 27, 2025 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Feb 27, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, corporate-reporting
Related Tickers: BCDA
TL;DR
BioCardia filed an 8-K, mostly routine stuff, no major news yet.
AI Summary
On February 27, 2025, BioCardia, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company, formerly known as Tiger X Medical, Inc., is incorporated in Delaware and headquartered in Sunnyvale, California.
Why It Matters
This 8-K filing indicates routine corporate reporting by BioCardia, Inc., providing updates on its operational and financial documentation to the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without disclosure of any significant adverse events or material changes.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- Tiger X Medical, Inc. (company) — Former company name
- February 27, 2025 (date) — Date of report
- 320 Soquel Way Sunnyvale, California 94085 (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for BioCardia, Inc.?
The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily concerning 'Other Events' and 'Financial Statements and Exhibits'.
When was this 8-K report filed?
The report was filed on February 27, 2025.
What is BioCardia, Inc.'s state of incorporation?
BioCardia, Inc. is incorporated in Delaware.
What was BioCardia, Inc.'s former company name?
BioCardia, Inc. was formerly known as Tiger X Medical, Inc.
Where are BioCardia, Inc.'s principal executive offices located?
BioCardia, Inc.'s principal executive offices are located at 320 Soquel Way, Sunnyvale, California 94085.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 27, 2025 regarding BioCardia, Inc. (BCDA).